| Eli Lilly and Daiichi Sankyo release positive prasugrel results in diabetes patients | Posted on 01/09/2008 in Pharmaceutical Company Product News Eli Lilly and Daiichi Sankyo have announced the results of a head-to-head study of prasugrel with clopidogrel in patients with diabetes.
The sub-group analysis of the Triton-Timi 38 trial showed a 30 per cent reduction in cardiovascular events in patients taking prasugrel compared to those administered with clopidogrel.
Furthermore, diabetic patients with acute coronary syndromes were 40 per cent less likely to suffer a heart attack if they were treated with prasurgrel rather than clopidogrel.
Results from this subanalysis were presented this week at the congress of the European Society of Cardiology in Munich, Germany, with the results also published online in Circulation, the American Heart Association journal.
Stephen Wiviott, assistant professor of medicine at Harvard Medical School, said: "The results observed from this sub-group analysis showed that antiplatelet therapy with prasugrel resulted in significantly greater reduction of cardiovascular events among patients with diabetes when compared to those who were treated with clopidogrel."
He added these findings are of interest given previous studies that showed a higher levels of platelet aggregation following dual antiplatelet therapy in insulin-treated diabetes patients compared to those not treated with insulin.
Last week, Eli Lilly and Daiichi Sankyo announced phase III results showing comparing prasugrel to clopidogrel, with patients taking the former experiencing a 35 per cent reduction in recurrent cardiovascular events.Other news stories from 01/09/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
